Comparative Pharmacology
Head-to-head clinical analysis: DOSTINEX versus REQUIP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOSTINEX versus REQUIP.
DOSTINEX vs REQUIP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by binding to D2 receptors on lactotroph cells in the anterior pituitary.
Dopamine receptor agonist; exhibits high affinity for D2 and D3 receptors, and moderate affinity for D1 and D4 receptors.
0.25 mg orally twice weekly, with a minimum of 2 days between doses; may increase by 0.25 mg twice weekly every 4 weeks up to a maximum of 1 mg twice weekly.
Immediate-release: Initial 0.25 mg orally three times daily; titrate weekly by 0.25 mg per dose to a total daily dose of 3 mg; max 24 mg/day. Extended-release: Initial 2 mg orally once daily; titrate by 2 mg/day at weekly intervals; max 24 mg/day.
None Documented
None Documented
The terminal elimination half-life is 63–69 hours in healthy volunteers and 79–115 hours in patients with hyperprolactinemia, allowing once- or twice-weekly dosing. The long half-life reflects slow dissociation from D2 receptors and enterohepatic recirculation.
Terminal elimination half-life: approximately 5-6 hours in young healthy adults, extending to 7-9 hours in elderly patients. Clinically, dosing is typically three times daily due to this short half-life.
Cabergoline is extensively metabolized in the liver, primarily via CYP3A4. Elimination is predominantly fecal (60%) and renal (20%) as metabolites, with <4% as unchanged drug. Biliary excretion contributes to fecal elimination.
Primarily renal: approximately 90% of the dose is excreted in urine, with about 60% as unchanged drug and 30% as metabolites. Fecal excretion accounts for about 10%.
Category C
Category C
Dopamine Agonist
Dopamine Agonist